Neville Rodie & Shaw Inc. Has $2.98 Million Stake in Gilead Sciences, Inc. (GILD)

Neville Rodie & Shaw Inc. lowered its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 23.6% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 42,130 shares of the biopharmaceutical company’s stock after selling 13,016 shares during the period. Neville Rodie & Shaw Inc.’s holdings in Gilead Sciences were worth $2,982,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the company. Keel Point LLC raised its stake in shares of Gilead Sciences by 0.4% during the first quarter. Keel Point LLC now owns 3,111 shares of the biopharmaceutical company’s stock valued at $211,000 after acquiring an additional 11 shares during the last quarter. West Oak Capital LLC raised its stake in shares of Gilead Sciences by 0.7% during the second quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock valued at $330,000 after acquiring an additional 32 shares during the last quarter. Westover Capital Advisors LLC raised its stake in shares of Gilead Sciences by 0.8% during the first quarter. Westover Capital Advisors LLC now owns 5,563 shares of the biopharmaceutical company’s stock valued at $378,000 after acquiring an additional 46 shares during the last quarter. Abner Herrman & Brock LLC raised its stake in shares of Gilead Sciences by 0.5% during the first quarter. Abner Herrman & Brock LLC now owns 10,202 shares of the biopharmaceutical company’s stock valued at $693,000 after acquiring an additional 50 shares during the last quarter. Finally, ARS Investment Partners LLC raised its stake in shares of Gilead Sciences by 0.9% during the first quarter. ARS Investment Partners LLC now owns 5,610 shares of the biopharmaceutical company’s stock valued at $381,000 after acquiring an additional 50 shares during the last quarter. 74.05% of the stock is owned by hedge funds and other institutional investors.

In other news, EVP Gregg H. Alton sold 5,000 shares of the firm’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $71.06, for a total transaction of $355,300.00. Following the sale, the executive vice president now owns 102,988 shares of the company’s stock, valued at approximately $7,318,327.28. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Robin L. Washington sold 51,820 shares of the firm’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the sale, the chief financial officer now directly owns 43,352 shares in the company, valued at approximately $3,684,920. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 466,819 shares of company stock worth $36,740,240. Insiders own 1.30% of the company’s stock.

WARNING: “Neville Rodie & Shaw Inc. Has $2.98 Million Stake in Gilead Sciences, Inc. (GILD)” was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://sportsperspectives.com/2017/09/17/neville-rodie-shaw-inc-has-2-98-million-stake-in-gilead-sciences-inc-gild.html.

Gilead Sciences, Inc. (GILD) traded up 0.09% on Friday, reaching $82.36. 12,401,948 shares of the company’s stock were exchanged. The firm’s 50 day moving average price is $77.16 and its 200 day moving average price is $70.20. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $86.27. The company has a market cap of $107.56 billion, a PE ratio of 8.95 and a beta of 1.19.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.11 by $0.45. The firm had revenue of $7.14 billion for the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The business’s quarterly revenue was down 8.2% compared to the same quarter last year. During the same quarter last year, the firm posted $3.08 EPS. On average, analysts expect that Gilead Sciences, Inc. will post $8.75 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.53%. The ex-dividend date is Thursday, September 14th. Gilead Sciences’s payout ratio is presently 22.58%.

A number of brokerages recently weighed in on GILD. Jefferies Group LLC reissued a “hold” rating and set a $80.00 target price on shares of Gilead Sciences in a research note on Tuesday, July 11th. BMO Capital Markets reissued an “outperform” rating and set a $82.00 target price (up previously from $72.00) on shares of Gilead Sciences in a research note on Thursday, July 27th. Robert W. Baird reissued an “outperform” rating and set a $87.00 target price on shares of Gilead Sciences in a research note on Thursday, July 13th. Leerink Swann reissued a “market perform” rating on shares of Gilead Sciences in a research note on Thursday, June 22nd. Finally, BidaskClub raised shares of Gilead Sciences from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 22nd. Eleven research analysts have rated the stock with a hold rating and twenty have given a buy rating to the company’s stock. Gilead Sciences presently has an average rating of “Buy” and a consensus target price of $83.79.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply